scholarly journals The frequency of acute atherosis in normal pregnancy and preterm labor, preeclampsia, small-for-gestational age, fetal death and midtrimester spontaneous abortion

2014 ◽  
Vol 28 (17) ◽  
pp. 2001-2009 ◽  
Author(s):  
Yeon Mee Kim ◽  
Piya Chaemsaithong ◽  
Roberto Romero ◽  
Majid Shaman ◽  
Chong Jai Kim ◽  
...  
2010 ◽  
Vol 95 (Supplement 1) ◽  
pp. Fa22-Fa22
Author(s):  
J. Leonce ◽  
N. Brockton ◽  
A. Burchell ◽  
S. Robinson ◽  
P. Steer ◽  
...  

2005 ◽  
Vol 90 (8) ◽  
pp. 4895-4903 ◽  
Author(s):  
Eiji Shibata ◽  
Augustine Rajakumar ◽  
Robert W. Powers ◽  
Robert W. Larkin ◽  
Carol Gilmour ◽  
...  

Context: An excess of the soluble receptor, fms-like tyrosine kinase 1 (sFlt-1) may contribute to maternal vascular dysfunction in women with preeclampsia by binding and thereby reducing concentrations of free vascular endothelial growth factor and placental growth factor (PlGF) in the circulation. The putative stimulus for increased sFlt-1 during preeclampsia, placental hypoxia due to poor perfusion, is common to both preeclampsia and idiopathic intrauterine growth restriction. However, the latter condition occurs without maternal vascular disease. Objective: We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates. Study Design: This was a case-control study using banked samples. Groups of women with SGA neonates (birth weight centile < 10th) and women with preeclampsia were matched to separate sets of normal pregnancy controls based on gestational age at blood sampling (serum) or gestational age at delivery (placenta). Results: sFlt-1 levels were higher in preeclamptics than controls (serum, P < 0.0001; placental protein, P = 0.03; placental mRNA, P = 0.007) but not increased in SGA pregnancies. PlGF was lower in both preeclampsia (serum, P < 0.0001; placental protein, P = 0.05) and SGA (serum, P = 0.0008; placental protein, P = 0.03) compared with their controls. PlGF in preeclampsia and SGA groups did not differ. Conclusions: These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.


2007 ◽  
Vol 26 (1) ◽  
pp. 101-109 ◽  
Author(s):  
Laura D. Jenkins ◽  
Robert W. Powers ◽  
Mary Adotey ◽  
Marcia J. Gallaher ◽  
Nina Markovic ◽  
...  

2013 ◽  
Vol 41 (6) ◽  
pp. 637-642 ◽  
Author(s):  
A. O. Odibo ◽  
A. G. Cahill ◽  
K. R. Goetzinger ◽  
L. M. Harper ◽  
M. G. Tuuli ◽  
...  

2005 ◽  
Vol 24 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Amanda Malina ◽  
Ashi Daftary ◽  
William Crombleholme ◽  
Nina Markovic ◽  
James M. Roberts

2017 ◽  
Vol 10 (4) ◽  
pp. 165-169 ◽  
Author(s):  
Mathieu Puyade ◽  
Emilie Cayssials ◽  
Fabrice Pierre ◽  
Olivier Pourrat

Background The most frequent myeloproliferative neoplasms are essential thrombocythemia and chronic myelogenous leukemia, which usually manifests with thrombocytosis. Only essential thrombocythemia is associated with morbidity during pregnancy (recurrent miscarriages, intrauterine fetal death, small for gestational age and preeclampsia). The aim of this paper is to describe outcomes of pregnancy in women with myeloproliferative neoplasms seen at a single academic institution. Methods Data were collected retrospectively from 2002 to 2015. Descriptive analyses were performed. Results Eighteen pregnancies in 13 patients and 17 births were identified. One patient had recurrent miscarriages. There were two intrauterine fetal deaths, three small for gestational age linked to vascular placenta pathology and one preeclampsia. All of these mothers harbored JAK2V617F mutation. Two out of three patients with small for gestational age developed a venous thrombosis in the two years following delivery. Conclusion Thrombocytosis associated with myeloproliferative neoplasms should be considered as a risk factor for maternal and fetal complications.


2012 ◽  
Vol 207 (4) ◽  
pp. 318.e1-318.e6 ◽  
Author(s):  
Rachel A. Pilliod ◽  
Yvonne W. Cheng ◽  
Jonathan M. Snowden ◽  
Amy E. Doss ◽  
Aaron B. Caughey

Sign in / Sign up

Export Citation Format

Share Document